Find, compare & contact
Toreforant API Manufacturers & Suppliers

teaser-1024x654-1
Contact suppliers
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Toreforant is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Toreforant or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Toreforant API 952494-46-1?

Description:
Here you will find a list of producers, manufacturers and distributors of Toreforant. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Toreforant 
Synonyms:
 
Cas Number:
952494-46-1 
DrugBank number:
DB12522 
Unique Ingredient Identifier:
U6LA7G393X

General Description:

Toreforant, identified by CAS number 952494-46-1, is a notable compound with significant therapeutic applications. Toreforant has been used in trials studying the treatment of Asthma, Psoriasis, Hepatic Impairment, and Rheumatoid Arthritis.

Classification:

Toreforant belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds), classified under the direct parent group Benzimidazoles. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Benzimidazoles class, specifically within the None subclass.

Categories:

Toreforant is categorized under the following therapeutic classes: Heterocyclic Compounds, Fused-Ring, Histamine Agents, Histamine Antagonists, Neurotransmitter Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Toreforant is a type of Anti-asthma


Anti-asthma pharmaceutical APIs are a category of active pharmaceutical ingredients (APIs) specifically developed to combat asthma, a chronic respiratory condition characterized by inflammation and narrowing of the airways. These APIs play a crucial role in the formulation of effective medications used to manage and treat asthma symptoms.

The primary objective of anti-asthma pharmaceutical APIs is to alleviate airway inflammation and bronchospasms, which are the major factors contributing to asthma attacks. These APIs target specific cellular receptors involved in the inflammatory response, such as leukotriene receptors and beta-2 adrenergic receptors.

Corticosteroids are a common class of anti-asthma APIs used to suppress inflammation in the airways. They work by inhibiting the production of inflammatory molecules, thereby reducing swelling and mucus production. Beta-2 agonists are another essential group of APIs that act on the beta-2 adrenergic receptors in the airway smooth muscles, leading to relaxation and opening of the airways.

Anti-asthma APIs are carefully synthesized and purified to meet stringent quality standards, ensuring their safety and efficacy. Extensive research and development efforts go into optimizing the pharmacological properties of these APIs, including their bioavailability, stability, and compatibility with different formulations.

Pharmaceutical companies utilize anti-asthma APIs to develop various dosage forms, including inhalers, tablets, and injections. These APIs are often combined with other excipients and technologies to enhance drug delivery and improve patient compliance.

In conclusion, anti-asthma pharmaceutical APIs are critical components in the development of medications that effectively manage asthma symptoms. They target key mechanisms underlying asthma pathophysiology, providing relief from airway inflammation and bronchospasms. These APIs enable the formulation of safe and efficient anti-asthma drugs, empowering individuals with asthma to lead healthier lives.